There are currently no disease-modifying treatments for Alzheimer’s disease (AD), and an
understanding of preclinical causal biomarkers to help target disease pathogenesis in the …

Background Education and cognition demonstrate consistent inverse associations with
Alzheimer’s disease (AD). The biological underpinnings, however, remain unclear. Blood …

Background Recent studies suggest that plasma phosphorylated tau181 (p-tau181) is a
highly specific biomarker for Alzheimer’s disease (AD)-related tau pathology. It has great …

Background: physiological differences between males and females could contribute to the
development of Alzheimer’s Disease (AD). Here, we examined metabolic pathways that may …

Background There is an urgent need to understand the pathways and processes underlying
Alzheimer’s disease (AD) for early diagnosis and development of effective treatments. This …

Attention-deficit/hyperactivity disorder (ADHD) persists in older age and is postulated as a
risk factor for cognitive impairment and Alzheimer’s Disease (AD). However, these findings …

Investigating associations between metabolites and late midlife cognitive function could
reveal potential markers and mechanisms relevant to early dementia. Here, we systematically …

Plasma phosphorylated tau at threonine-181 (P-tau181) demonstrates promise as an
accessible blood-based biomarker specific to Alzheimer's Disease (AD), with levels recently …

… Jodie Lord is funded by the van Geest endowment fund. Richard Dobson is supported by
the following: (1) NIHR Biomedical Research Centre at South London and Maudsley NHS …

Background Identifying blood-based signatures of brain health and preclinical pathology may
offer insights into early disease mechanisms and highlight avenues for intervention. Here, …